E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Dilated Cardiomyopathy (DCM) with Lamin A/C protein (LMNA) Mutation |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10056419 |
E.1.2 | Term | Dilated cardiomyopathy |
E.1.2 | System Organ Class | 100000004849 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
NYHA Class II/III patients only: Evaluate the effect of ARRY-371797 (PF-07265803) on functional capacity (as measured by the 6-minute walk test [6MWT]) compared to placebo |
|
E.2.2 | Secondary objectives of the trial |
- Evaluate additional measures of efficacy of ARRY-371797 (PF-07265803) compared to placebo in the randomized period. - Evaluate the impact of ARRY-371797 (PF-07265803) on composite of all-cause mortality, or worsening heart failure (WHF). - Evaluate the impact of ARRY-371797 (PF-07265803) on overall survival (OS). - Evaluate the safety of ARRY-371797 (PF-07265803) compared to placebo |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Selected Key Inclusion Criteria: • Provide a signed and dated informed consent document prior to initiation of any study-related procedures. Patients under guardianship or partial guardianship will be eligible unless prohibited by local laws or by local/central ethic committees • Age ≥ 18 years at time of informed consent • Patients with symptomatic lamin A/C protein (LMNA)-related cardiomyopathy Class II/III/ or Class IV defined as: a. Gene positive for a pathogenic, likely pathogenic or VUS mutation in the LMNA gene as determined by an accredited clinical laboratory b. NYHA functional Class II or III that has been stable for at least 3 months c. Evidence of cardiac impairment as determined by LVEF≤ 50% • Patient will have an implantable cardioverter defibrillator/cardiac resynchronization therapy defibrillator (ICD/CRT-D). ICD implanted at least 4 weeks prior to initiation of study treatment or CRT-D initiated at least 6 months prior to initiation of study intervention and defibrillation function activated at least 4 weeks prior to initiation of study intervention. Devices must have activated pacing capabilities or a separate pacemaker must be present. • Class II/III patients must have objective functional impairment evidenced by a reduction in 6-minute walk test (6MWT); • Stable medical and/or device therapy consistent with American Heart Association (AHA) / American College of Cardiology (ACC) or European Society of Cardiology (ESC) guidelines • Patients must meet acceptable hematology, hepatic and renal laboratory values as specified within 35 days prior Day 1
Please refer to Protocol, section 5.1 for detailed list of Inclusion Criteria.
|
|
E.4 | Principal exclusion criteria |
Selected Key Exclusion Criteria: • Presence of other form(s) of cardiomyopathy contributing to HF (e.g., inflammatory or infiltrative cardiomyopathy) or clinically significant cardiac anatomic abnormality (e.g., LV aneurysm), clinically significant coronary artery disease (e.g., coronary revascularization, exercise-induced angina) or uncorrected, hemodynamically significant (i.e., moderate-severe) primary structural valvular disease not due to HR, per Investigator judgment. • Currently receiving or deemed at high risk of requiring chronic renal replacement therapy (e.g., hemodialysis or peritoneal dialysis) within 6 months. • Treatment with any investigational agent(s) for HF within 35 days prior to Day 1. • Malignancy that is active or has been diagnosed within 3 years prior to screening, except surgically curatively resected in situ malignancies or surgically cured early breast cancer, prostate cancer, skin cancer (basal cell carcinoma, squamous cell carcinoma) thyroid cancer or cervical cancer, or, with prior review by the Medical Monitor, other earlystage surgically curatively resected malignancies with less than a 20% expected 2-year recurrence rate. • Non-cardiac condition that limits lifespan to < 1 year. • Serum positive for hepatitis B surface antigen, viremic hepatitis C, or human immunodeficiency virus (HIV) at screening. • Pregnancy or breastfeeding, or patients who plan to become pregnant during the duration of the trial • Patients with an underlying condition that may impact the ability of the 6MWT to reflect changes in cardiovascular function such as: an orthopedic condition that limits walking abilities (e.g., severe arthritis), significant musculoskeletal pathology, significant chronic obstructive pulmonary disease (COPD) that limits exercise tolerance or any other condition that according to the Investigator's assessment significantly limits a patient's performance on the 6MWT independently from the patient's cardiomyopathy. • Documented hypersensitivity/allergy or clinically significant intolerance to any component of drug product.
Please refer to Protocol, section 5.2 for detailed list of Exclusion Criteria. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
NYHA Class II/III patients only: Change from baseline in 6MWT at Week 24 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. NYHA Class II/III patients only: Change from baseline in 6MWT at Weeks 4 and 12 2. NYHA Class II/III patients only: Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Physical Limitation (PL) and Total Symptom Score (TSS) domains at Weeks 12 and 24 3. NYHA Class II/III patients only: Change from baseline in Patient Global Impression (PGI) scores at Weeks 12 and 24 - Patient Global Impression of Severity (PGI-S) - Patient Global Impression of Change (PGI-C) 4. NYHA Class II/III patients only: Change from baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP) at Weeks 4, 12 and 24 5. HFS: defined as the time from randomization to the first occurence of any event in the composite of death due to any cause, or worsening heart failure (HF-related hospitalization or HF-related urgent care visit). 6. OS 8. Safety as determined by: - Incidence and severity of adverse events (AEs) - Changes in clinical safety laboratory tests, vital signs and 12-lead electrocardiograms (ECGs) - Incidence and severity of ventricular or atrial arrhythmias detected using existing implantable cardioverter defibrillator (ICD)/cardiac resynchronization therapy defibrillator (CRT-D) or other applicable device interrogations at Weeks 12 and 24,
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Weeks 4 and 12 2. Weeks 12 and 24 3. Weeks 12 and 24 4. Weeks 4, 12 and 24 5. Thoughout the duration of the study 7. Throughout the duration of the study 8. Safety endpoints throughout the duration of the study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Randomized, double-blind treatment period followed by open-label treatment period |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 50 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Mexico |
United States |
Belgium |
France |
Germany |
Italy |
Netherlands |
Norway |
Spain |
United Kingdom |
Argentina |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is reached when all patients enrolled into the randomized portion of the study have had the opportunity to be followed for at least 24 weeks in the open-label or have discontinued from the study, whichever comes first |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |